Midazolam and drug–drug interactions in dental conscious sedation

Hdl Handle:
http://hdl.handle.net/10147/315347
Title:
Midazolam and drug–drug interactions in dental conscious sedation
Authors:
Broderick, Damian; Clarke, Mary; Stassen, Leo
Citation:
Broderick, Damian, Clarke, Mary, Stassen, Leo. Midazolam and drug–drug interactions in dental conscious sedation. Journal of the Irish Dental Association March 2014.
Publisher:
Irish Dental Association
Journal:
Journal of the Irish Dental Association
Issue Date:
Mar-2014
URI:
http://hdl.handle.net/10147/315347
Abstract:
Midazolam is an imidazobenzodiazepine, which was first synthesised in 1976 by Fryer and Walser. Its favourable properties include a reduced half life, high lipophilicity and a pH of 3.5, which enables it to be water soluble in the preparatory ampoule. This subsequently allowed for painless intravenous administration, in contrast with diazepam, where thrombophlebitis had been commonly reported at the site of administration. Midazolam soon became an alternative to diazepam and soon superseded it as the mainstay pharmacological agent for intravenous sedation. It has a therapeutic range of between 2mg and 7mg when administered intravenously.1
Item Type:
Article
Language:
en
Keywords:
DENTAL HEALTH
Local subject classification:
MIDAZOLAM

Full metadata record

DC FieldValue Language
dc.contributor.authorBroderick, Damianen_GB
dc.contributor.authorClarke, Maryen_GB
dc.contributor.authorStassen, Leoen_GB
dc.date.accessioned2014-04-04T09:56:28Z-
dc.date.available2014-04-04T09:56:28Z-
dc.date.issued2014-03-
dc.identifier.citationBroderick, Damian, Clarke, Mary, Stassen, Leo. Midazolam and drug–drug interactions in dental conscious sedation. Journal of the Irish Dental Association March 2014.en_GB
dc.identifier.urihttp://hdl.handle.net/10147/315347-
dc.description.abstractMidazolam is an imidazobenzodiazepine, which was first synthesised in 1976 by Fryer and Walser. Its favourable properties include a reduced half life, high lipophilicity and a pH of 3.5, which enables it to be water soluble in the preparatory ampoule. This subsequently allowed for painless intravenous administration, in contrast with diazepam, where thrombophlebitis had been commonly reported at the site of administration. Midazolam soon became an alternative to diazepam and soon superseded it as the mainstay pharmacological agent for intravenous sedation. It has a therapeutic range of between 2mg and 7mg when administered intravenously.1en_GB
dc.language.isoenen
dc.publisherIrish Dental Associationen_GB
dc.subjectDENTAL HEALTHen_GB
dc.subject.otherMIDAZOLAMen_GB
dc.titleMidazolam and drug–drug interactions in dental conscious sedationen_GB
dc.typeArticleen
dc.identifier.journalJournal of the Irish Dental Associationen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.